Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma

  • Almazan Moga, Ana
  • Zarzosa Martinez, Patricia
  • Vidal Marin, Isaac
  • Molist Muñoz, Carla
  • Giralt Buch, Irina
  • Soriano Fernández, Aroa
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Gallego Melcón, Soledad
  • Navarro Barea, Natalia
Tumors dels teixits tous; Via Hedgehog; Rabdomiosarcoma, Tumores de los tejidos blandos; Vía Hedgehog; Rabdomiosarcoma, Soft tissue neoplasms; Hedgehog pathway; Rhabdomyosarcoma, Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and can be divided into two main subtypes: embryonal (eRMS) and alveolar (aRMS). Among the cellular heterogeneity of tumors, the existence of a small fraction of cells called cancer stem cells (CSC), thought to be responsible for the onset and propagation of cancer, has been demonstrated in some neoplasia. Although the existence of CSC has been reported for eRMS, their existence in aRMS, the most malignant subtype, has not been demonstrated to date. Given the lack of suitable markers to identify this subpopulation in aRMS, we used cancer stem cell-enriched supracellular structures (spheres and holoclones) to study this subpopulation. This strategy allowed us to demonstrate the capacity of both aRMS and eRMS cells to form these structures and retain self-renewal capacity. Furthermore, cells contained in spheres and holoclones showed significant Hedgehog pathway induction, the inhibition of which (pharmacologic or genetic) impairs the formation of both holoclones and spheres. Our findings point to a crucial role of this pathway in the maintenance of these structures and suggest that Hedgehog pathway targeting in CSC may have great potential in preventing local relapses and metastases., The authors wish to thank Dr. Noel Monks (MedImmune) for the kind gift of the blocking antibody MEDI-5304 and Ms. Christine O’Hara for help with the English version of this manuscript. This work was supported by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (RTICC-RD12/0036/0016 and RD12/0036/0027; PI11/00740 and PI14/00647), Fundació A. BOSCH, and ajuts predoctorals VHIR.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes

  • Soriano, Aroa|||0000-0001-9659-1471
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Jubierre Zapater, Luz
  • Martínez, Alba
  • Zhou, Xiangyu
  • Piskareva, Olga
  • Bray, Isabella
  • Vidal, Isaac
  • Almazán-Moga, Anna
  • Molist, Carla|||0000-0003-3251-0083
  • Roma, Josep|||0000-0001-7692-6123
  • Bayascas Ramírez, José Ramón|||0000-0002-6096-2151
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Stallings, Raymond L.
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
Despite multimodal therapies, a high percentage of high-risk neuroblastoma (NB) become refractory to current treatments, most of which interfere with cell cycle and DNA synthesis or function, activating the DNA damage response (DDR). In cancer, this process is frequently altered by deregulated expression or function of several genes which contribute to multidrug resistance (MDR). MicroRNAs are outstanding candidates for therapy since a single microRNA can modulate the expression of multiple genes of the same or different pathways, thus hindering the development of resistance mechanisms by the tumor. We found several genes implicated in the MDR to be overexpressed in high-risk NB which could be targeted by microRNAs simultaneously. Our functional screening identified several of those microRNAs that reduced proliferation of chemoresistant NB cell lines, the best of which was miR-497. Low expression of miR-497 correlated with poor patient outcome. The overexpression of miR-497 reduced the proliferation of multiple chemoresistant NB cell lines and induced apoptosis in MYCN-amplified cell lines. Moreover, the conditional expression of miR-497 in NB xenografts reduced tumor growth and inhibited vascular permeabilization. MiR-497 targets multiple genes related to the DDR, cell cycle, survival and angiogenesis, which renders this molecule a promising candidate for NB therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma

  • Almazán-Moga, Anna
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Vidal, Isaac
  • Molist, Carla|||0000-0003-3251-0083
  • Giralt, Irina|||0000-0002-9094-4325
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Soriano, Aroa|||0000-0001-9659-1471
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Alfranca, Arantzazu|||0000-0002-3732-5816
  • Garcia-Castro, Javier|||0000-0001-7604-1640
  • Sánchez de Toledo, Joan|||0000-0002-9108-4750
  • Roma, Josep|||0000-0001-7692-6123
  • Gallego, Soledad|||0000-0002-4712-9624
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and can be divided into two main subtypes: embryonal (eRMS) and alveolar (aRMS). Among the cellular heterogeneity of tumors, the existence of a small fraction of cells called cancer stem cells (CSC), thought to be responsible for the onset and propagation of cancer, has been demonstrated in some neoplasia. Although the existence of CSC has been reported for eRMS, their existence in aRMS, the most malignant subtype, has not been demonstrated to date. Given the lack of suitable markers to identify this subpopulation in aRMS, we used cancer stem cell-enriched supracellular structures (spheres and holoclones) to study this subpopulation. This strategy allowed us to demonstrate the capacity of both aRMS and eRMS cells to form these structures and retain self-renewal capacity. Furthermore, cells contained in spheres and holoclones showed significant Hedgehog pathway induction, the inhibition of which (pharmacologic or genetic) impairs the formation of both holoclones and spheres. Our findings point to a crucial role of this pathway in the maintenance of these structures and suggest that Hedgehog pathway targeting in CSC may have great potential in preventing local relapses and metastases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma, the oncogenic role of the ligands

  • Almazán-Moga, Anna
  • Zarzosa, Patricia|||0000-0002-9711-8384
  • Molist, Carla|||0000-0003-3251-0083
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Pyczek, Joanna
  • Simon-Keller, Katja|||0000-0003-2340-8765
  • Giralt, Irina|||0000-0002-9094-4325
  • Vidal, Isaac
  • Navarro Barea, Natalia|||0000-0002-2160-6656
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Soriano, Aroa|||0000-0001-9659-1471
  • Navarro, Susanna|||0000-0001-8160-9536
  • Tirado, Òscar Martínez
  • Ferreres Piñas, Joan Carles|||0000-0001-7742-0239
  • Santamaria, Anna
  • Rota, Rossella
  • Hahn, Heidi
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Roma, Josep|||0000-0001-7692-6123
  • Gallego, Soledad|||0000-0002-4712-9624
Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children. The Hedgehog (HH) pathway is known to develop an oncogenic role in RMS. However, the molecular mechanism that drives activation of the pathway in RMS is not well understood. The expression of HH ligands was studied by qPCR, western blot and immunohistochemistry. Functional and animal model studies were carried out with cells transduced with shRNAs against HH ligands or treated with HH-specific inhibitors (Vismodegib and MEDI-5304). Finally, the molecular characterisation of an off-target effect of Vismodegib was also made. The results showed a prominent expression of HH ligands supporting an autocrine ligand-dependent activation of the pathway. A comparison of pharmacologic Smoothened inhibition (Vismodegib) and HH ligand blocking (MEDI-5304) is also provided. Interestingly, a first description of pernicious off-target effect of Vismodegib is also reported. The clarification of the HH pathway activation mechanism in RMS opens a door for targeted therapies against HH ligands as a possible alternative in the future development of better treatment protocols. Moreover, the description of a pernicious off-target effect of Vismodegib, via unfolded protein response activation, may mechanistically explain its previously reported inefficiency in several ligand-dependent cancers.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma

  • Soriano, Aroa|||0000-0001-9659-1471
  • Masanas, Marc|||0000-0002-2249-8554
  • Boloix, Ariadna|||0000-0002-1648-5589
  • Masiá, Núria
  • París-Coderch, Laia|||0000-0003-2145-5752
  • Piskareva, Olga
  • Jiménez Jiménez, Carlos|||0000-0001-9219-3492
  • Henrich, Kai-Oliver
  • Roma, Josep|||0000-0001-7692-6123
  • Westermann, Frank
  • Stallings, Raymond L.
  • Sábado, Constantino|||0000-0003-3956-5466
  • Sánchez de Toledo Codina, José|||0000-0002-1034-1920
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Gallego, Soledad|||0000-0002-4712-9624
  • Segura, Miguel F.|||0000-0003-0916-3618
The online version of this article (10.1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users., Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. RNA therapeutics is an emerging field that widens the range of druggable targets and includes elements such as microRNA. Here, we sought to screen for microRNA with tumor-suppressive functions in neuro-blastoma, an aggressive pediatric tumor of the sympathetic nervous system that requires the development of new therapies. We found miR-323a-5p and miR-342-5p to be capable of reducing cell proliferation in multiple neuroblastoma cell lines in vitro and in vivo, thereby providing a proof of concept for miRNA-based therapies for neuroblastoma. Furthermore, the combined inhibition of the direct identified targets such as CCND1, CHAF1A, INCENP and BCL-XL could reveal new vulnerabilities of high-risk neuroblastoma.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma

  • Almazan Moga, Ana
  • Zarzosa Martinez, Patricia
  • Vidal Marin, Isaac
  • Molist Muñoz, Carla
  • Giralt Buch, Irina
  • Soriano Fernández, Aroa
  • Segura Ginard, Miguel
  • Sánchez de Toledo Codina, Josep
  • Roma Castanyer, Josep
  • Gallego Melcón, Soledad
  • Navarro Barea, Natalia
Tumors dels teixits tous; Via Hedgehog; Rabdomiosarcoma, Tumores de los tejidos blandos; Vía Hedgehog; Rabdomiosarcoma, Soft tissue neoplasms; Hedgehog pathway; Rhabdomyosarcoma, Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and can be divided into two main subtypes: embryonal (eRMS) and alveolar (aRMS). Among the cellular heterogeneity of tumors, the existence of a small fraction of cells called cancer stem cells (CSC), thought to be responsible for the onset and propagation of cancer, has been demonstrated in some neoplasia. Although the existence of CSC has been reported for eRMS, their existence in aRMS, the most malignant subtype, has not been demonstrated to date. Given the lack of suitable markers to identify this subpopulation in aRMS, we used cancer stem cell-enriched supracellular structures (spheres and holoclones) to study this subpopulation. This strategy allowed us to demonstrate the capacity of both aRMS and eRMS cells to form these structures and retain self-renewal capacity. Furthermore, cells contained in spheres and holoclones showed significant Hedgehog pathway induction, the inhibition of which (pharmacologic or genetic) impairs the formation of both holoclones and spheres. Our findings point to a crucial role of this pathway in the maintenance of these structures and suggest that Hedgehog pathway targeting in CSC may have great potential in preventing local relapses and metastases., The authors wish to thank Dr. Noel Monks (MedImmune) for the kind gift of the blocking antibody MEDI-5304 and Ms. Christine O’Hara for help with the English version of this manuscript. This work was supported by grants from Institut Català d’Oncologia (ICO), Instituto de Salud Carlos III (RTICC-RD12/0036/0016 and RD12/0036/0027; PI11/00740 and PI14/00647), Fundació A. BOSCH, and ajuts predoctorals VHIR.